When Medical Devices Go Wrong – 10 High-Risk Products Exposed 

27 May 2026

Medical devices play a vital role in diagnosing, treating, and improving patients’ lives. Most undergo extensive testing and perform safely, but history shpws that some devices have entered the market with serious flaws, sometimes due to rushed development, insufficient clinical evidence, or inadequate post-market oversight.. 

This blog highlights ten high-profile medical devices that failed after reaching patients. These cases demonstrate why rigorous testing, strong regulatory scrutiny, and continuous post-market surveillance are essential to ensuring that medical technology truly benefits patients rather than putting them at risk. 

The medtech industry often argue approval pathways take too long and delay innovation, while patient advocates worry the faster  access cam compromise safety.  

Although most devices in the U.S. and Europe are safe, some unsafe products still reach the market. For example, an Olympus endoscope linked to deadly superbug infections was marketed without FDA clearance. This situation shows how challenging it is to balance speed and safety in regulation. 

Ten Case Studies for Medical Device Manufacturers and Providers

1. Metal-on-Metal Hips: A Medical Device Misstep 

Metal-on-metal hip implants first came onto the scene in the late 1990s, touted as stronger and more durable than other designs, except for ceramic implants, which were considered hard but brittle. But it soon became clear that these metal implants did not perform as manufacturers had hoped. 

In some cases, the implants released chromium and cobalt ions, triggering inflammatory reactions that led to osteolysis, the breakdown of bone tissue around the implant. These ions could build up in the tissue around the implant, damaging bone and muscle. If they entered the bloodstream, they could harm organs like the kidneys, liver, spleen, and lymph nodes before being flushed out. 

When Johnson & Johnson’s DePuy Orthopaedics launched its all-metal hip implant in 2005, it was cleared through the FDA’s 510(k) process, claiming that it was equivalent to older models to skip new clinical investigations. But a decade later, due to high failure rates, the company faced nearly $3 billion in lawsuits related to recalled ASR metal-on-metal hips, as well aslawsuits involving the Pinnacle Acetabular Cup System. 

In 2013, The New York Times described metal-on-metal hip implants as “one of the biggest medical device failures in recent decades.” 

2. The Vaginal Mesh Controversy: What You Need to Know 

Vaginal mesh devices were originally designed to treat urinary incontinence. But between 2008 and 2010, the FDA received thousands of reports about serious complications—from mesh eroding through the vaginal wall to pain, infections, bleeding, painful intercourse, organ perforation, and urinary dysfunction. 

• Lawsuits soon flooded against major companies, including Boston Scientific, Johnson & Johnson’s Ethicon, American Medical Systems, Endo International, C.R. Bard, Cook Medical, and Coloplast. 

• The vaginal mesh controversy mirrors the metal-on-metal hip implant crisis. 

• In the late 1990s, the FDA accepted claims that vaginal meshes were substantially equivalent to surgical mesh used for hernia repair. 

• However, as ProPublica pointed out, the mesh was inserted through the vaginal wall—not via abdominal surgery—and used for a completely different purpose. 

• These mesh “kits” were marketed as a new and improved treatment for urinary incontinence. 

Despite growing evidence of harm, the FDA continued to describe serious mesh complications as “rare” until 2008. By mid-2011, the agency acknowledged those complications were not uncommon, prompting stricter regulatory scrutiny. 

3. When Defibrillator Leads Go Wrong: A Closer Look 

In 2011, St. Jude Medical recalled its Riata family of implantable cardioverter-defibrillators (ICD) leads after discovering that the internal cables could erode through the outer casing, sometimes delivering unintended shocks to patients. Even now, about 90,000 Riata and Riata ST leads remained implanted worldwide.. Earlier this year, St. Jude agreed to pay over $14 million to settle 950 lawsuits related to these leads. 

Critics, including ProPublica, cited the Riata case as evidence of weaknesses in post-market surveillance. A U.S. Government Accountability Office report highlighted several issues, includint reliance on voluntary reports and lacking full information on device usage and patients. 

The problems didn’t completely end there. St. Jude’s follow-up product, the Durata leads, was designed to fix these issues but has faced safety concerns as well. In 2014, Medscape reported a near-fatal failure in one patient’s Durata lead, which, upon analysis, showed internal abrasion and other defects. 

Similar post-market issues have also affected Medtronic’s Sprint Fidelis cardiac leads in recent years, underscoring the importance of long-term monitoring for implantable devices. 

4. When Duodenoscopes Spread Infection: A Medical Wake-Up Call 

Duodenoscopes are specialized endoscopes that travel through the digestive tract into the small intestine. In the U.S., they’re made by companies like Olympus, Fujifilm, and Pentax and are used in about half a million procedures each year. 

• One of Olympus’s latest models, the TJF-Q180V, was linked to a deadly outbreak at UCLA’s Ronald Reagan Medical Center.  

• At least seven patients were infected with the drug-resistant bacteria carbapenem-resistant Enterobacteriaceae (CRE), and two died.  

• The hospital bestimated that as many as 179 patients may have been exposed. 

Lawsuits alleged that Olympus had modified the device’s design without adequately updating cleaning instructions and without submitting the changes for FDA 510(k). clearanceOlympus maintained that regulatory submission was not required and that no definitive link existed between the design change and the infections.. 

Eventually, Olympus submitted the device for 510(k) clearance, which led to revised cleaning protocols: smaller brushes, extra flushing steps, and adjustments to how the forceps elevator is cleaned. 

5. The Hidden Risks of Trilucent Breast Implants 

In the early 1990s, Dr. Leroy Young proposed filling breast implants with soybean oil as an alternative to silicone, which was subject to a U.S. FDA moratorium at the time. They also claimed the soybean oil implants would last longer than silicone or saline ones and interfere less during mammograms. 

The soy-based implants, called Trilucent, were launched in Europe in 1995, and about 5,000 women received them. But soon, reports of implant leakage started to emerge. By 1999, the UK advised against using these implants, and the FDA never approved them in the United States. 

6. Behind the Ventak Prizm ICD Malfunction 

In 2005, Guidant Corp. recalled its Ventak Prizm ICD after discovering the device could short-circuit andfail to deliver a life-saving shock during a cardiac arrest. The recall affected nearly 200,000 of these devices. 

That same year, several class action lawsuits alleged the company of had been aware of the defect before notifying regulators. Guidant eventually settled the claims out of court for $16.8 million. But in April 2010, the company pleaded guilty to misleading the FDA about the issues with the Ventak and two other ICD models. 

7. The Hidden Dangers of the Axxent Flexishield Mini 

The Axxent Flexishield Mini, Model 5300, was cleared through the 510(k) pathway, and designed to be temporarily placed in breast incisions to reduce radiation exposure during intraoperative radiation therapy. The device was made from silicone-wrapped tungsten. 

In 2010, 30 women treated with the Flexishield were found to have high levels of tungsten in their breast tissue, prompting the FDA to recall the device a year later. While the long-term effects of tungsten exposure inside the body aren’t fully understood, a 2005 study from the Uniformed Services University of the Health Sciences linked tungsten exposure to cancer growth in animals. Additionally, tungsten can interfere mammograms by appearing similar to calcifications, potentially confusing imaging. 

8. Baxter Colleague Pump Problems: Understanding the Risk 

In 2005, Baxter decided to withdraw all models of its Colleague volumetric infusion pump from the global market after identifying a serious defect that could cause the pump to shut off unexpectedly during drug or fluid delivery. The company received alerts about six injuries and three deaths linked to this malfunction. At the time, about 255,000 of these pumps were in use worldwide, including 206,000 in the U.S. The FDA had originally cleared the device back in 1996. 

9. The Morcellator Recall: Lessons in Patient Safety 

Last year, Johnson & Johnson’s Ethicon unit halted sales of its power morcellators after the FDA warned that these devices could accidentally spread cancer during fibroid removal. Ethicon’s spokesman, Matthew Johnson, told Qmed that the company’s morcellators weren’t being recalled—the morcellators function as intended—but there was now uncertainty about their risks and benefits. 

Around the same time, Intuitive Surgical lowered its sales forecasts after the FDA warned about morcellators, since these devices sometimes work with Intuitive’s surgical robots. 

10. PIP Breast Implants Controversy  

One of the biggest recent medical device scandals in Europe was the Poly Implant Prothèse (PIP) breast implant crisis. Made with industrial-grade silicone, these implants l ed to widespread concern and regulatory reform across Europe. 

Jean-Claude Mas, the founder of PIP, was convicted of fraud and sentenced to four years in prison—the harshest sentence for that charge. He was also fined €75,000. The scandal directly contributed to stricter oversight of medical devices in the EU and ultimately influenced the development of the EU Medical Device Regulation. 

Conclusion  

Medical devices have the power to save lives and improve health, but when they fail, the consequences can be severe. These ten examples remind us that we must always pair innovation with rigorous testing, strict regulation, and ongoing oversight. Whether it’s faulty implants, malfunctioning cardiac devices, or unsafe surgical tools, safety lapses not only harm patients but also erode trust in the healthcare system.  

These examples highlight the critical role of regulators, manufacturers, and healthcare providers in ensuring that devices are safe and effective before reaching patients—and that problems are quickly identified and addressed when they arise. 

Ultimately, protecting patient safety requires constant vigilance, transparency, and accountability. By learning from these failures, the medical community can work toward a future where technology truly enhances care without compromising the well-being of those who depend on it. 

Building Safer Medical Devices with TS Quality & Engineering

At TS Quality & Engineering, we understand that when medical devices fail, the consequences can be critical. That’s why we specialize in risk management, ISO compliance, and advanced testing frameworks to help manufacturers identify vulnerabilities before they reach patients.

From high‑risk implants to connected medical technologies, our team provides the expertise needed to strengthen safety, ensure regulatory compliance, and restore trust in healthcare innovation. With capabilities in 3D printing solutions and cutting‑edge material validation, we help companies not only prevent failures but also pioneer safer, smarter devices for the future.